Christopher Hunter

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Recommended - Individuals: transactions

Blake, Cassels & Graydon’s IP practice has had another banner year, with long-term client relationships and an excellent reputation in court serving as the keys to its success. It has earned the trust of many of the most important players in the pharmaceutical arena, as well as the ever-growing cannabis sector. The twin pillars of the litigation practice, Andrew Skodyn and Melanie Baird are trial-savvy lawyers who have been enlisted to represent Pharmacyclics and Janssen in two separate actions brought under the PM(NOC) Regulations. Both matters concern Natco and relate to its blockbuster medication that is used to treat a wide range of cancers and is one of the world’s best-selling drugs. On the cannabis front, the duo has also been assisting Willow Biosciences in the first patent infringement case in Canada involving cannabinoid synthesis in the cannabis industry before the Federal Court. Commercial IP lead Christopher Hunter also has significant instructions keeping him occupied, and of late has been working closely with Guidestar Medical Devices to draft and file a US provisional application, followed by a PCT application; he continues to provide his support while working with foreign associates on the company’s global prosecution strategy.

Unlock unlimited access to all IAM content